Navigation Links
Takeda to Acquire Inviragen, Inc.
Date:5/7/2013

) is transmitted via mosquito and can cause fever, headache, fatigue, nausea, vomiting, muscle pain, rash and joint pain in those infected. Approximately 30% of patients showing clinical signs experience incapacitating joint pain, or arthritis that may persist for weeks, months, or in some cases years. On rare occasions, CHIKV infection may lead to neurologic and hepatic disease with high illness and mortality rates. CHIKV is considered endemic in 34 countries in Europe, Australia, Asia and Africa.

About Inviragen, Inc.
Inviragen is focused on developing vaccines to protect against infectious diseases worldwide. Inviragen's vaccine to protect against dengue fever is in Phase 2 clinical testing. A vaccine designed to protect children from hand, foot and mouth disease has completed Phase 1 clinical testing. Vaccines to protect against chikungunya and Japanese encephalitis, which affect millions of individuals in Asia, are in development.  Vaccines in preclinical research stages include vaccines to protect against new forms of influenza and a combination plague/smallpox vaccine for biodefense. Founded in 2005 with offices in Colorado, Wisconsin and Singapore, Inviragen's investors include EDBI (through Bio*One Capital, Singapore), Charter Life Sciences (Sunnyvale, CA), Venture Investors (Madison, WI), and Phillip Private Equity (Singapore). See www.inviragen.com for more details.

About Takeda Pharmaceutical Company Limited
Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in '/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Takeda Responds to Verdict in Diabetes Drug Case
2. Takeda Launches New Subsidiary in Ecuador
3. Takeda lanza nueva subsidiaria en Ecuador
4. Scripps Research Institute and Takeda Pharmaceuticals Announce Expanded Research Collaboration
5. Takeda presenta la richiesta di autorizzazione allimmissione in commercio nellUnione Europea per Vedolizumab nella colite ulcerosa moderata-grave e nella malattia di Crohn
6. Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohns Disease in the European Union
7. Takeda and Resolve Therapeutics Enter Autoimmune Partnership
8. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
9. FDA Accepts Takeda and Lundbecks Submission of the New Drug Application for Vortioxetine for the Treatment of Major Depressive Disorder
10. Takedas Deerfield Campus Ranked Among Chicagos Top 100 Workplaces in 2012
11. Takeda Completes its Russian Pharmaceutical Manufacturing Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Texas , Sept. 2, 2014  XBiotech ... III study being conducted in the US for ... True Human™ monoclonal antibody therapy, is being evaluated ... further complicated with cachexia. The primary endpoint of ... Xilonix treated patients to a control population provided ...
(Date:9/2/2014)... 2014   Santa Clara dentist , Dr. ... for Invisalign. Invisalign is an orthodontic system that uses ... often the orthodontic treatment of choice for older teens ... it. For a limited time, patients can try Invisalign ... the usual cost. This offer cannot be combined, and ...
(Date:9/2/2014)... , September 2, 2014 ... CONGRESS 2014 provide insight into treatment and outcomes ... clinical practice --   Data from ... Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF), an innovative, ... prevention strategies for atrial fibrillation (AF) patients remain ...
Breaking Medicine Technology:XBiotech Halts Study, Reports Positive Phase III Results with Antibody Therapy for Cancer 2Santa Clara Cosmetic Dentist, Dr. Alan Frame, is Now Offering a Special on Invisalign 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9
... DIEGO, May 31, 2012 Halozyme Therapeutics, Inc. (NASDAQ: ... Jefferies 2012 Global Healthcare Conference in New York on ... PT . Kurt Gustafson, Chief Financial Officer, Halozyme ... http://photos.prnewswire.com/prnh/20100302/LA63139LOGO ) The presentation will ...
... American Pharmacists Association (APhA), a DC-based, non-profit professional ... announced that on Monday evening, May 28, 2012, ... and defaced by an unknown individual or group.  ... APhA considers any attack on its ...
Cached Medicine Technology:Halozyme Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference 2
(Date:9/3/2014)... Job seekers who are interested in expanding their ... do both on iHire. By incorporating MOOCtracks into the ... investigating employment and educational opportunities in the same place. ... skills gaps and challenging the landscape of education by ... and mortar universities. To make it easier for their ...
(Date:9/3/2014)... Morris Psychological Group , ... for depression on October 9, 2014 from 4:30-8:30 ... than 1,000 organizations nationwide will be hosting National ... military installations. After completing a screening, participants will ... that can offer further evaluation and treatment if ...
(Date:9/3/2014)... (PRWEB) September 03, 2014 Joulebody, the ... 20 day custom healthy detox and weight-loss program ... Why?,     Because it’s good for ... clean-out their body. ,     Because using an elimination ... the countless testimonials of clients letting go of caffeine, ...
(Date:9/2/2014)... September 03, 2014 Autumn is ... wants to celebrate the new season with worldwide ... research and announced that Hostgator ( http://secure.hostgator.com/~affiliat/cgi-bin/affiliates/clickthru.cgi?id=seohosts ), ... suppliers of 2014. , Since 2002 HostGator ... provider, and the company’s reputation for reliability remains ...
(Date:9/2/2014)... The symptoms of dry eye disease include the sensation ... burning and visual disturbance. The causes are poorly understood., ... aged 20 to 87 (average age 57) from the ... Thomas, Hospital in London., This cohort is widely regarded ... been used to look at a wide range of ...
Breaking Medicine News(10 mins):Health News:iHire Announces Partnership with MOOCtracks 2Health News:Screenings for Depression by Morris Psychological Group, October 9, 2014 from 4:30 to 8:30pm, Rockaway Townsquare Mall (Macy’s Court) 2Health News:Joulebody Launches a Besoke 20-Day Healthy Lifestyle Program 2Health News:Joulebody Launches a Besoke 20-Day Healthy Lifestyle Program 3Health News:Joulebody Launches a Besoke 20-Day Healthy Lifestyle Program 4Health News:Top10BestSEOHosting.com Celebrates The Coming Of Autumn And Release Reseller Hosting Suppliers Of 2014 2Health News:Around 1 in 10 UK women has dry eye disease, requiring artificial tears 2
... at understanding the influences of paternity on the brain, ... of their close// resemblance with humans. Tiny monkeys called ... valuable insight into how fatherhood can actually ... found that there were structural changes in the brain ...
... increasing the time that kids spend in exercise will not ... weight. //Economist John Cawley of Cornell University and colleagues found ... of students taking part in physical education decreased from 42% ... examined data on 37,000 teens in grades nine through 12. ...
... first trimester could be associated with cardiac abnormalities in ... septal defects, Journal Birth Defects Research Part B, Trimester, ... who take non-steroidal anti-inflammatory drugs (NSAIDs) early in their ... babies with congenital defects. ,The findings of ...
... attention now a days experts have began to ponder as ... //for their own good. ,There are now a ... health groups, like the World Health Organization, the U.S. Centers ... Pediatrics as to if baby fat, which is usually a ...
... mosquito-borne encephalitis B in China, the Beijing News said on ... already killed by the disease. ,In central Henan ... and 40 of them have died so far. These infections ... months of 2006. But the newspaper did not explain why ...
... issue of the Journal, Vascular Surgery, researchers at the University ... put people younger than 60 more at risk of premature ... the study done on nearly 2,500 people younger than 60 ... ,Peripheral vascular disease is a narrowing of blood vessels ...
Cached Medicine News:Health News:NSAIDs In First trimester Linked To Congenital Anomalies In Babies 2Health News:Chubbiness In Babies Might Not Be A Cute Sign 2
Utrata-like fine angled tips with gently curved shaft for performing capsulorhexis through tunnel incisions. Dull finish. Flat handle....
McPherson handle. 45 degree angled shafts. Manufactured in titanium....
This cross action forcep has delicate tips for grasping the capsule. The forcep has an iris stop to prevent inadvertent grasping of the iris....
Similar in construction to the E2002 Utrata Capsulorhexis Forceps with jaw set to open only 3 mm. Flat handle with dull finish....
Medicine Products: